In this study, we evaluated for the first time the antitumor effects of PAFR and EGFR targeting strategies in ovarian cancer cell lines using the PAFR antagonist WEB2086 and EGFR inhibitor AG1478. The gene discussed is PTAFR; the disease is ovarian carcinoma.